SCHEMBL4133903

SCHEMBL4133903

Cc1ccc(S(=O)(=O)NC(=O)Cc2ccc(NC3=NC(=O)C(=Cc4ccc(-n5cnnn5)c(OCc5ccccc5)c4)S3)cc2)cc1.[NaH]

nearest known ligand 0.41

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.40
LMNA P02545 3/20 0.40
PKM P14618 1/20 0.40
KMT2A Q03164 2/20 0.38
CISD1 Q9NZ45 1/20 0.37
POLB P06746 2/20 0.36
MAPT P10636 2/20 0.36
HPGD P15428 1/20 0.36
RECQL P46063 1/20 0.36
NPC1 O15118 1/20 0.35
RAB9A P51151 1/20 0.35
PAX8 Q06710 1/20 0.35
ENPP2 Q13822 2/20 0.35
AKR1B1 P15121 1/20 0.35
EGFR P00533 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4133898 1.00 ALDH1A1 (0.40) ALDH1A1LMNAPKMKMT2ACISD1
SCHEMBL4140726 0.88 PTPN1 (0.40) ALDH1A1LMNAPKMMAPTEGFR
SCHEMBL4140728 0.88 PTPN1 (0.40) ALDH1A1LMNAPKMMAPTEGFR
SCHEMBL4131993 0.83 LMNA (0.45) ALDH1A1LMNAKMT2APOLBMAPT
SCHEMBL4131998 0.83 LMNA (0.45) ALDH1A1LMNAKMT2APOLBMAPT
Acetic Acid SCHEMBL4127844 0.82 CISD1 (0.44) KMT2ACISD1ENPP2AKR1B1
Acetic Acid SCHEMBL4127847 0.82 CISD1 (0.44) KMT2ACISD1ENPP2AKR1B1
SCHEMBL4133773 0.81 EGFR (0.41) ALDH1A1LMNAKMT2AMAPTHPGD
SCHEMBL4133774 0.81 EGFR (0.41) ALDH1A1LMNAKMT2AMAPTHPGD
SCHEMBL4133775 0.81 EGFR (0.42) ALDH1A1LMNAKMT2AMAPTHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090088432-A1 Thiazolinones and Oxazolinones and their Use as Ptp1b Inhibitors TORRENT PHARMACEUTICALS LIMITED (IN) 2009-04-02 US claimed
EP-1934192-A1 THIAZOLINONES AND OXAZOLINONES AND THEIR USE AS PTP1B INHIBITORS Torrent Pharmaceuticals Ltd (IN) 2008-06-25 EP claimed
WO-2007032028-A1 THIAZOLINONES AND OXAZOLINONES AND THEIR USE AS PTP1B INHIBITORS TORRENT PHARMACEUTICALS LTD. (IN) 2007-03-22 WO claimed
US-20090088432-A1 Thiazolinones and Oxazolinones and their Use as Ptp1b Inhibitors TORRENT PHARMACEUTICALS LIMITED (IN) 2009-04-02 US disclosed
EP-1934192-A1 THIAZOLINONES AND OXAZOLINONES AND THEIR USE AS PTP1B INHIBITORS Torrent Pharmaceuticals Ltd (IN) 2008-06-25 EP disclosed
WO-2007032028-A1 THIAZOLINONES AND OXAZOLINONES AND THEIR USE AS PTP1B INHIBITORS TORRENT PHARMACEUTICALS LTD. (IN) 2007-03-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090088432-A1 Thiazolinones and Oxazolinones and their Use as Ptp1b Inhibitors PTPRF, PTPA, PTPRJ ALDH1A1 216/4885LMNA 4619/4885PKM 1500/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.